Neurogene Inc NGNE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Neurogene Inc. Announces Pricing of $125 Million Public Offering
-
Neurogene Inc. Announces Proposed Public Offering
-
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
-
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
-
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
-
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Trading Information
- Previous Close Price
- $39.08
- Day Range
- $37.73–40.00
- 52-Week Range
- $15.93–43.66
- Bid/Ask
- $38.00 / $46.00
- Shares Outstanding
- 19.95M
- Market Cap
- $787.04M
- Volume/Avg
- 181,687 / 211,883
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 131
- Website
- https://www.neurogene.com
Valuation
|
Metric
|
NGNE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.59 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NGNE
|
|---|---|
Quick Ratio | 12.90 |
Current Ratio | 13.08 |
Interest Coverage | −36,412.00 |
Quick Ratio
NGNE
Profitability
|
Metric
|
NGNE
|
|---|---|
Return on Assets (Normalized) | −29.22% |
Return on Equity (Normalized) | −31.83% |
Return on Invested Capital (Normalized) | −34.31% |
Return on Assets
NGNE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^>!m%%s | LOCK|s?rQ | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@y??%ym | LOCK|<M<& | $70B | |||
| argenx SE ADR
ARGX
| LOCK|R!?D<?J | LOCK|&W# | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@hcS>f | LOCK|&xlQK | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|N!!<S<K | LOCK|Sd> | $37B | |||
| Moderna Inc
MRNA
| LOCK|&!$x<tZ | LOCK|KR | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>!YXNp^ | LOCK|>q>V | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|@HTvM$^ | LOCK|YR> | $23B | |||
| Incyte Corp
INCY
| LOCK|?k<QK<d | LOCK|Q?z | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Y#^&h?L | LOCK|QV# | $16B |
United States